Purdue Institute for Drug Discovery

Darunavir

Overview: 

FDA approved for treatment for drug resistant HIV

PREZISTA (darunavir) information

Status: 

Purdue Faculty: 

Dr. Arun Ghosh

Clinical Trial Information: 

All Darunavir Clinical Trials

Development Partner: 

Janssen Therapeutics

Research Articles: 

Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro

Bis-Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active Against Multi-drug-resistant Clinical Strains

Effectiveness of Nonpeptide Clinical Inhibitor TMC-114 on HIV-1 Protease with Highly Drug Resistant Mutations D30N, I50V, and L90M